Cam Donaldson

Christopher Davison

David Williams

Fahn

Jim Lloyd

John T. O'Brien

Karl Herholz

Kirsty Olsen

Michael J. Firbank

Nicky Barnett

Robert Barber

Roth

Schmidt

Sean J. Colloby

English

BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission tomography (FDG-PET).AimsTo investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET scan.MethodParticipants had a clinical diagnosis of Alzheimer's disease (n = 37) or dementia with Lewy bodies (DLB; n = 30) or were similarly aged controls (n = 30). We visually rated MTLA on coronally reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET scans.ResultsUsing a pre-defined cut-off of MTLA ≥5 on the Scheltens (0-8) scale, 0/30 controls, 6/30 DLB and 23/30 Alzheimer's disease had marked MTLA. FDG-PET performed well for diagnosing Alzheimer's disease v. DLB in the low-MTLA group (sensitivity/specificity of 71%/79%), but in the high-MTLA group diagnostic performance of FDG-PET was not better than chance.ConclusionsIn the presence of a high degree of MTLA, the most likely diagnosis is Alzheimer's disease, and an FDG-PET scan will probably not provide significant diagnostic information. However, in cases without MTLA, if the diagnosis is unclear, an FDG-PET scan may provide additional clinically useful diagnostic information

Firbank, Michael J

Lloyd, Jim

Williams, David

Barber, Robert

Colloby, Sean J

Barnett, Nicky

Olsen, Kirsty

Davison, Christopher

Donaldson, Cam

Herholz, Karl

O'Brien, John T

The University of Manchester - Institutional Repository

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy.

BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe
                           atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance
                           imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose
                           positron emission tomography (FDG-PET).AimsTo investigate whether MTLA on head CT predicts the diagnostic usefulness
                           of an additional FDG-PET scan.MethodParticipants had a clinical diagnosis of Alzheimer's disease
                              (n = 37) or dementia with Lewy bodies (DLB;
                              n = 30) or were similarly aged controls
                              (n = 30). We visually rated MTLA on coronally
                           reconstructed CT scans and, separately and blind to CT ratings, abnormal
                           appearances on FDG-PET scans.ResultsUsing a pre-defined cut-off of MTLA ⩾5 on the Scheltens (0–8) scale, 0/30
                           controls, 6/30 DLB and 23/30 Alzheimer's disease had marked MTLA. FDG-PET
                           performed well for diagnosing Alzheimer's disease v. DLB
                           in the low-MTLA group (sensitivity/specificity of 71%/79%), but in the
                           high-MTLA group diagnostic performance of FDG-PET was not better than
                           chance.ConclusionsIn the presence of a high degree of MTLA, the most likely diagnosis is
                           Alzheimer's disease, and an FDG-PET scan will probably not provide
                           significant diagnostic information. However, in cases without MTLA, if
                           the diagnosis is unclear, an FDG-PET scan may provide additional
                           clinically useful diagnostic information.</jats:sec

Crossref

The British Journal of Psychiatry

An evidence-based algorithm for the utility of FDG-PET for
                        diagnosing Alzheimer's disease according to presence of medial temporal lobe
                        atrophy

Background: Imaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission tomography (FDG-PET). Aims: To investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET scan. Method: Participants had a clinical diagnosis of Alzheimer's disease (n = 37) or dementia with Lewy bodies (DLB; n = 30) or were similarly aged controls (n = 30). We visually rated MTLA on coronally reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET scans. Results: Using a pre-defined cut-off of MTLA ≥ 55 on the Scheltens (0-8) scale, 0/30 controls, 6/30 DLB and 23/30 Alzheimer's disease had marked MTLA. FDG-PET performed well for diagnosing Alzheimer's disease v. DLB in the low-MTLA group (sensitivity/specificity of 71%/79%), but in the high-MTLA group diagnostic performance of FDG-PET was not better than chance. Conclusions: In the presence of a high degree of MTLA, the most likely diagnosis is Alzheimer's disease, and an FDG-PET scan will probably not provide significant diagnostic information. However, in cases without MTLA, if the diagnosis is unclear, an FDG-PET scan may provide additional clinically useful diagnostic information

Firbank, Michael

Lloyd, JJ

Williams, ED

Barber, R

Colloby, SJ

Barnett, NA

Olsen, K

Davison, C

Herholz, K

O'Brien, JT

ResearchOnline@GCU

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy

https://researchonline.gcu.ac.uk/files/23869203/C.Donaldson_SUSPAD_PET_CT_guidelines_submitBJP_authorVersion_1_.pdf

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy

Abstract

Similar works

Full text

Available Versions

The University of Manchester - Institutional Repository

Crossref

ResearchOnline@GCU